Overview Bioequivalence Study of Atazanavir 300 mg Capsule Status: Completed Trial end date: 2006-12-01 Target enrollment: Participant gender: Summary The purpose of this clinical research study is to assess the bioequivalence of atazanavir administered as a single 300 mg capsule relative to two atazanavir 150 mg capsules in healthy subjects. Phase: Phase 1 Details Lead Sponsor: Bristol-Myers SquibbTreatments: AripiprazoleAtazanavir SulfateRitonavir